Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Transitioning from non-PBS to PBS-subsidised treatment - Grandfather arrangements

Patient must have received non-PBS-subsidised treatment with this drug for this PBS condition prior to 1 May 2025; AND

The condition must have relapsed, or be refractory to, at least two prior systemic therapies, prior to commencing treatment with this drug; AND

Patient must have had a WHO performance status of no higher than 2 prior to commencing treatment with this drug for this condition; AND

Patient must have previously received treatment with chimeric antigen receptor-T (CAR-T) cell therapy for this condition; or

Patient must have been unable to receive treatment with CAR-T cell therapy for this condition; AND

Patient must not be eligible for stem cell transplantation; AND

The treatment must be discontinued in patients who experience disease progression whilst on treatment; AND

Patient must be undergoing treatment with this drug administered weekly in cycles 1 to 3 - prescribe up to 9 repeats; or

Patient must be undergoing treatment with this drug administered fortnightly in cycles 4 to 9 - prescribe up to 5 repeats; or

Patient must be undergoing treatment with this drug administered every four weeks in cycles 10 and beyond - prescribe up to 2 repeats.

Prior systemic therapy may include autologous stem cell transplant.

Definition of patients unable to receive treatment with CAR-T cell therapy for this condition include geographical, psychosocial, clinical ineligibility or urgency.